Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations (Q37890550)

24 August 2017

1 reference

title

Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations (English)

1 reference

24 August 2017

1 reference

1 reference

1 reference

2

Azita Haddadi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21679733

4 December 2024

author name string

Samar Hamdy

1

1 reference

24 August 2017

Afsaneh Lavasanifar

4

1 reference

24 August 2017

Ryan W. Hung

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21679733

4 December 2024

language of work or name

English

0 references

publication date

6 June 2011

1 reference

full work available at URL

24 August 2017

https://api.elsevier.com/content/article/PII:S0169409X11001438?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

https://api.elsevier.com/content/article/PII:S0169409X11001438?httpAccept=text/plain

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Advanced Drug Delivery Reviews

4 December 2024

published in

1 reference

24 August 2017

volume

63

1 reference

24 August 2017

issue

10-11

1 reference

24 August 2017

page(s)

943-955

1 reference

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

24 August 2017

cites work

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1038/73193

Cancer immunotherapy

1

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Passive antibody therapies: progress and continuing challenges

4 December 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.

4 December 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Cancer immunotherapy: moving beyond current vaccines

4 December 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization

4 December 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention

4 December 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation.

4 December 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Gene-based strategies for the immunotherapy of cancer

4 December 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Poly(I:C) coated PLGA microparticles induce dendritic cell maturation.

4 December 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients.

4 December 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

4 December 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations

4 December 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector

4 December 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Tumour prevention and rejection with recombinant vaccinia.

4 December 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Characterization of tumor vaccines during product development

4 December 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency

4 December 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Cell biology of antigen processing in vitro and in vivo

4 December 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy

4 December 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Improving vaccines by targeting antigens to dendritic cells

4 December 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Phagocytosis of microbes: complexity in action

4 December 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

The role of chemokines in linking innate and adaptive immunity

4 December 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites

4 December 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination

4 December 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo

4 December 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Dynamics of CD8 T cell priming by dendritic cells in intact lymph nodes

4 December 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures

4 December 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal

4 December 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Cross-presentation: inducing CD8 T cell immunity and tolerance

4 December 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Cross-presentation, dendritic cells, tolerance and immunity

4 December 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens

4 December 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells

4 December 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Phagosomes are competent organelles for antigen cross-presentation

4 December 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

ER quality control: the cytoplasmic connection

4 December 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Immunology: professional secrets

4 December 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages

4 December 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4 and CD8 T cell responses in humans

4 December 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo

4 December 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Proliferating dendritic cell progenitors in human blood

4 December 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34( ) hematopoietic progenitor cells

4 December 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Immune and clinical responses in patients with metastatic melanoma to CD34( ) progenitor-derived dendritic cell vaccine

4 December 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

4 December 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Making the connections in nerve regeneration

4 December 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen

4 December 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients

4 December 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

4 December 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

4 December 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Dendritic cell gene therapy

4 December 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

4 December 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state

4 December 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Immunostimulatory colloidal delivery systems for cancer vaccines.

4 December 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Promising particle-based vaccines in cancer therapy.

4 December 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

4 December 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

4 December 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices

4 December 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

PLGA nanoparticles in drug delivery: the state of the art.

4 December 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery

4 December 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice

4 December 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.

4 December 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response.

4 December 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses

4 December 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres

4 December 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Encapsulation of plasmid DNA in biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery

4 December 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Improving protein therapeutics with sustained-release formulations

4 December 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study

4 December 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro

4 December 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer

4 December 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Challenges facing adjuvants for cancer immunotherapy

4 December 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

4 December 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Biodegradable polymers for the sustained release of peptides

4 December 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Biodegradable Polymers for Protein and Peptide Drug Delivery

4 December 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Biodegradable microspheres as a vaccine delivery system

4 December 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios

4 December 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Degradation rates of polymers and copolymers of polylactic and polyglycolic acids

4 December 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives

4 December 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines

4 December 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses

4 December 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles

4 December 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro

4 December 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells

4 December 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines

4 December 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Targeting vaccines to dendritic cells

4 December 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Targeting dendritic cells with biomaterials: developing the next generation of vaccines

4 December 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo

4 December 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Strategies for vaccine delivery

4 December 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Vaccines that facilitate antigen entry into dendritic cells.

4 December 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Uptake of HIV and latex particles by fresh and cultured dendritic cells and monocytes

4 December 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity

4 December 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates

4 December 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery

4 December 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Design and development of polymers for gene delivery

4 December 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer

4 December 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines

4 December 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

The transporter associated with antigen processing: function and implications in human diseases

4 December 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Toll-like receptor ligands energize peptide vaccines through multiple paths

4 December 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

4 December 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Toll pathway-dependent blockade of CD4 CD25 T cell-mediated suppression by dendritic cells

4 December 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Control of Foxp3 CD25 CD4 regulatory cell activation and function by dendritic cells

4 December 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells

4 December 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance

4 December 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

4 December 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery

4 December 2024

111

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo

4 December 2024

112

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses

4 December 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity

4 December 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

"Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells

4 December 2024

115

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Enhanced antigen-specific primary CD4 and CD8 responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles

4 December 2024

116

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses

4 December 2024

117

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma

4 December 2024

118

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology

4 December 2024

119

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

CD4 cells can be more efficient at tumor rejection than CD8 cells

4 December 2024

120

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Interferon-γ: an overview of signals, mechanisms and functions

4 December 2024

122

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8 T cell-mediated anti-tumor immunity

4 December 2024

123

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Toll-dependent selection of microbial antigens for presentation by dendritic cells

4 December 2024

124

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Natural killer T cells: rapid responders controlling immunity and disease

4 December 2024

125

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

CD1: antigen presentation and T cell function

4 December 2024

126

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

4 December 2024

127

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

4 December 2024

128

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Augmented induction of CD8 cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.

4 December 2024

129

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

4 December 2024

130

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4( ) T cell-dependent mechanism

4 December 2024

131

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4 and CD8 T cell immunity against B16 melanoma

4 December 2024

132

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Cytoplasmic delivery of a macromolecular fluorescent probe by poly(d, l-lactic-co-glycolic acid) microspheres

4 December 2024

133

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells.

4 December 2024

134

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Natural-killer cells and dendritic cells: "l'union fait la force".

4 December 2024

135

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.

4 December 2024

136

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2011.05.021

4 December 2024

Identifiers

1 reference

release_ycdcmzjlvbhqtbfsdtwwrhn2vm

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ycdcmzjlvbhqtbfsdtwwrhn2vm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference